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Diabetic nephropathy is one of the most important complications of diabetes mellitus (1). Recently much attention has been directed toward the 
use of silymarin in diabetic nephropathy (2). Silymarin 
possesses antioxidant and antiproteinuric effects in humans 
and in animal models (2,3). Silymarin seems to have two 
different effects in diabetic patients (2,3). Firstly control 
of blood sugar and secondly, silymarin seems to have the 
ability to ameliorate the diabetic nephropathy, an effect 
beyond controlling the blood glucose in diabetics (2-4). 
In diabetic nephropathy, excessive generation of reactive 
oxygen species and the overproduction of superoxide, 
initiate the podocyte injury, which is a major contributor 
to the pathogenesis of diabetic kidney disease (2-4). 
Various studies have shown that silymarin should be a good 
medication to prevent nephropathy-induced premature 
death in diabetic patients (2-4). Moreover, it was observed 
that silymarin had a good protective effect against high 
glucose-induced podocyte injury too (2-5). Accordingly, 
to find out the kidney protective properties of silymarin 
and deferoxamine against iron dextran-induced renal iron 
deposition in male rats, we also conducted an investigation. 
We studied rats, which were allocated to six groups and 
injected iron dextran intraperitoneal for a period of 4 
weeks every other day, but at the beginning of the third 
week, they also were subjected to a 2-week (every other 
day) treatment with vehicle (group 2, positive control), 
silymarin (group 3), deferoxamine (group 4), silymarin 
(group 5) or combination of silymarin and deferoxamine 
(group 6). In this study, the levels of serum creatinine, iron, 
ferritin, blood urea nitrogen, and nitrite were determined 
and the kidneys were removed for histopathological 
investigations. Silymarin and deferoxamine treatments 
reduced the intensity of the kidney iron deposition, but only 
in the silymarin group a significant reduction in kidney 
iron deposition was observed. We concluded that silymarin 
is a renoprotective herb against injurious insult of iron 
deposition in the kidneys of animal models (6). Recently, 
much attention has been made on the possible kidney 
protective properties of metformin, too (7-9). To find out the 
potential efficiency of metformin to renal protection against 
gentamicin-induced acute renal injury and also to examine 
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Implication for health policy/practice/research/medical education:
Silymarin possesses antioxidant and antiproteinuric effects in humans and in animal 
models. Silymarin seem to have two different effects in diabetic patients. Firstly control 
of blood sugar and secondly, silymarin seems to have the ability to ameliorate the diabetic 
nephropathy, an effect beyond controlling the blood glucose in diabetics.
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whether postpone treatment with metformin in acute 
renal injury, exerts similar benefits on gentamicin-kidney 
toxicity in rats, we conducted a study on Wistar rats (10). 
In our study metformin was able to prevent and attenuate 
gentamicin-induced acute kidney damage (10). Hence, it 
might be beneficial in patients under treatment with this 
drug (9-14). Furthermore, silymarin extract could safely be 
used together with metformin to increase the antioxidant 
potency and better renoprotection, beyond the control of 
diabetes (9-14). In addition, Fallahzadeh et al investigated 
the effect of addition of silymarin to renin angiotensin 
system inhibitors on proteinuria in type 2 diabetic patients 
with overt nephropathy. They found that silymarin was 
able to reduce urinary excretion of albumin, TNF-a, and 
malondialdehyde in patients with diabetic kidney disease. 
This might be considered as a novel addition to the anti-
diabetic nephropathy (15). Thus, silymarin extract could 
safely co-administered together with metformin to increase 
the antioxidant potency and better kidney protection, 
beyond the control of blood glucose (7-10). Also, according 
to the kidney protective efficacy of silymarin in our 
study and its blood glucose regulatory effects by previous 
investigators and also effective reduction of urinary 
albumin excretion in the study of Fallahzadeh et al., it is 
possible that, the combination of metformin, silymarin 
and a renin-angiotensin system inhibitor or angiotensin 
receptor blocker may have additive kidney protective 
property, beyond controlling the blood sugar, to prevent or 
to slow the progression of diabetic nephropathy (12-15). In 
this regard, to better understand the renal protective effect 
of silymarin, especially when combined with metformin, 
more experimental rat models or clinical studies suggests. 
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